Investing.com -- Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock plummeted 51% in pre-market trading after the company announced it would sell its cell therapy assets to US WorldMeds for $55 million ...

TD Bank Group ("TD" or the "Bank") (TSX:TD) (NYSE:TD), is pleased to announce the appointment of John B. MacIntyre as Chair of the Board of Directors, effective September 1, 2025. His deep financial ...

New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...

CNW/ - As Canada looks to encourage greater economic growth amid shifting economic and geopolitical forces, new research from TD reveals that many ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Investment firm TD Cowen believes Apple has until the end of 2026 to make Apple Intelligence compelling, and in the meantime ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

As the Nasdaq composite added 50.36 points and the S&P 500 increased 25.29 points to end a robust week on July 25, companies are under pressure to provide substantial profit growth to support ...

Stryker Corporation (NYSE:SYK) is one of the top low volatility healthcare stocks to buy now. In a report released on July 20 ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...

A working robotaxi is one thing; finding customers is another. Operators like Waymo and WeRide have thus far tended toward ...

In a report released today, William Katz from TD Cowen reiterated a Buy rating on Invesco, with a price target of $29.00. The company’s shares opened today at $21.55. Take advantage of TipRanks ...